Respiri Limited announced that Brad Snow has been appointed as a Non-Executive Director of Respiri. Mr. Snow will commence in the role on June 20, after 25 years of extensive commercial, operations and business development experience, gained within the med-tech, biotech and HIT industries primarily focused in the United States. His deep experiences in healthcare stakeholders including providers, payors and Physicians, with emphasis in reimbursement system including remote patient monitoring. He brings a proven track record of achieving corporate turnarounds, leading start-ups and driving emerging companies to achieve revenue growth. Mr. Snow is currently Chief Executive Officer and Board of Director of Angel-Medical Systems Inc. (AngelMed).
AngelMed's novel device, The Guardian System, is the world's first and only FDA approved real-time implantable cardiac device to detect acute coronary syndrome events, including silent heart attacks. Previous, Brad was Chief Executive Officer and Board of Director of SonaCare Medical, LLC (now Sonablate Corp), a global company with a cutting edge (HIFU) ultrasound imaging, assessment and ablation system. Under his leadership, SonaCare carried out a successful capital raise and also secured a substantial sales distribution agreement. Mr. Snow provided Med-Tech Consulting which provided advisory services to medical technology clients in relation to commercial strategy, operational improvements, business development and funding. During the same
period, he also co-founded DisruptRxtech.com, an artificial intelligence healthcare IT company. Earlier in his career, Mr. Snow held executive leadership roles in sales, marketing and commercial operations for numerous start-up and emerging growth companies: BTGplc, ARAGON Surgical, Rubicor, Fox Hollow Technologies etc. in the med-tech space.